The operational recovery continued in Q2 23, with improving plasma collections and cost-saving initiatives supporting the top-line growth and profitability. Consequently, the 2023 guidance was upgraded ‘again’. However, investors seemed unimpressed with the results, as they lagged Takeda’s performance this quarter. On a broader level, normalising operations and progress on divestment initiatives, which support our strong BUY recommendation, should alleviate the market’s concerns around Grifols’ ....
27 Jul 2023
Good Q2; now all eyes on potential divestments
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Good Q2; now all eyes on potential divestments
- Published:
27 Jul 2023 -
Author:
Abhishek Raval -
Pages:
4
The operational recovery continued in Q2 23, with improving plasma collections and cost-saving initiatives supporting the top-line growth and profitability. Consequently, the 2023 guidance was upgraded ‘again’. However, investors seemed unimpressed with the results, as they lagged Takeda’s performance this quarter. On a broader level, normalising operations and progress on divestment initiatives, which support our strong BUY recommendation, should alleviate the market’s concerns around Grifols’ ....